As Introduced
Skip to main content
Kansas Legislature
kslegislature.gov
menu
Home
House
account_balanceAbout the House
groupsRepresentatives
campaignEvents
chairSeating Chart
auto_storiesJournals & Calendars
manage_accountsChief Clerk of the House
gavelRules
Senate
account_balanceAbout the Senate
groupsSenators
campaignEvents
assignment_indAppointments
chairSeating Chart
auto_storiesJournals & Calendars
manage_accountsSecretary of the Senate
gavelRules
Committees
groupsCommittees
eventHearing Schedule
handshakeConference Committee Schedule
Measures & Laws
gavelAll Measures
account_balanceHouse Measures
account_balanceSenate Measures
account_balanceVotes
topicSubject Index
summarizeReports
menu_bookStatutes
schoolHow a Bill Becomes Law
menu_bookLegislative Procedure Manual
Today
campaignLive Floor Activity
videocamHouse Video
videocamSenate Video
live_tvStatehouse Live & Archive
smart_displayYouTube Channel
Resources
Archive
Search
description
Go to bill or resolution
arrow_forward
A−
A+
search
Search bills, resolutions, and statutes
help
In-State: 1-800-432-3924
Out-of-State: 785-296-2149
Keywords
Enter any words to search bills, statutes, and documents.
water quality funding
Bill or Resolution Number
Type a number and press Enter to go directly to the detail page.
HB 2590 SCR 1611
Statute Number
68-102 72-3715
Exact Phrase
Wrap your query in quotes.
“rules of evidence”
Document Type
Prefix with a type to narrow results.
testimony: HB 2513 minutes: budget
Searching…
No results found.
search Search bills, resolutions, and statutes Home House About the House Representatives Events Seating Chart Journals & Calendars Chief Clerk of the House Rules Senate About the Senate Senators Events Appointments Seating Chart Journals & Calendars Secretary of the Senate Rules Committees All Committees Hearing Schedule Conference Committee Schedule Measures & Laws All Measures House Measures Senate Measures Votes Subject Index Reports Statutes How a Bill Becomes Law Legislative Procedure Manual Resources Today Live Floor Activity House Video Senate Video Statehouse Live & Archive YouTube Channel Archive Search- SB 212›
- SB 212 — As Introduced
Kansas Legislature
SB 212 — As Introduced
picture_as_pdf Download PDF Session of 2025SENATE BILL No. 212By Senator Sykes2-51AN ACT concerning health and healthcare; enacting the prescription drug 2cost and affordability review act; establishing the prescription drugs 3pricing board and prescription drug affordability stakeholder council to 4review the cost of prescription medications and establish upper 5payment limits for certain prescription drug products.67Be it enacted by the Legislature of the State of Kansas:8Section 1. This act shall be known and may be cited as the 9prescription drug cost and affordability review act.10Sec. 2. As used in sections 1 through 8, and amendments thereto:11(a) "340B-covered entity" means an entity that is participating in the 12federal 340B drug pricing program authorized by 42 U.S.C. § 256b, 13including such entity's pharmacy or pharmacies, or any pharmacy or 14pharmacies contracted for the purpose of dispensing drugs purchased 15through such program.16(b) "Biologic" means a drug that is produced or distributed in 17accordance with a biologics license application approved by the United 18States food and drug administration.19(c) "Biosimilar" means a drug that is produced or distributed in 20accordance with a biologics license application approved under 42 U.S.C. 21§ 262(k).22(d) "Board" means the prescription drug affordability board created in 23section 3, and amendments thereto.24(e) "Brand name drug" means a drug other than an authorized generic 25drug that is produced or distributed in accordance with an original new 26drug application approved under 21 U.S.C. § 355.27(f) "Commissioner" means the commissioner of insurance.28(g) "Consumer price index" means the United States consumer price 29index for all urban consumers as defined and reported by the United States 30department of labor, bureau of labor statistics.31(h) "Council" means the prescription drug affordability stakeholder 32council created in section 4, and amendments thereto.33(i) "Department" means the Kansas insurance department.34(j) "Fund" means the prescription drug affordability fund created in 35section 7, and amendments thereto.36(k) "Generic drug" means any of the following:1(1) A retail drug that is marketed or distributed in accordance with an 2abbreviated new drug application approved under 21 U.S.C. § 355;3(2) an authorized generic drug as such term is defined in 42 C.F.R. 4447.502; or 5(3) a drug that entered the market before 1962 that was not originally 6marketed under a new drug application.7(l) "Health insurer" means the same as defined in K.S.A. 40-4602, 8and amendments thereto.9(m) "Manufacturer" means the same as defined in K.S.A. 65-1626, 10and amendments thereto;11(n) "Person" means an individual, corporation or other legal entity.12(o) "Pharmacy" means the same as defined in K.S.A. 65-1626, and 13amendments thereto.14(p) "Prescription drug product" means a brand name drug, a generic 15drug, a biologic or a biosimilar.16(q) "Prescription drug product purchaser" means an entity that 17purchases and takes ownership of a prescription drug product for resale or 18providing to patients.19(r) "Rule" means a rule and regulation adopted by the board.20(s) "Third-party payor" means a payor that reimburses a pharmacy for 21drugs or services, including a pharmacy benefits manager. "Third-party 22payor" does not include the Kansas program of medical assistance under 23K.S.A. 39-709, and amendments thereto, or a managed care organization 24providing state medicaid or children's health insurance program services 25under the Kansas medical assistance or the state healthcare benefits 26program.27(t) "Wholesale acquisition cost" means such term as defined in 42 28U.S.C. § 1395w-3a(c)(6)(B).29Sec. 3. (a) There is hereby established the prescription drug 30affordability board as created as an autonomous entity within the 31department.32(b) (1) The board shall consists of five members, which shall be 33appointed by the governor. The members of the board shall include 34individuals who have expertise in healthcare economics, health policy, 35health equity and clinical medicine.36(2) The governor shall not appoint an individual to the board if the 37individual:38(A) Is employed by, a consultant to or a board member of a 39manufacturer or a trade association for a manufacturer;40(B) has a personal or financial interest that has the potential to bias or 41has the appearance of biasing the individual's decision in matters related to 42the board or in conducting the board's activities; or43(C) is a lobbyist who is registered in this state.1(3) An individual who is appointed to the board shall not register as a 2lobbyist in this state for a period of five years after the individual's term on 3the board expires.4(4) The governor shall appoint two of the initial members of the 5board to one-year terms and three of the initial members to two-year terms. 6After the initial appointments, the term of a member of the board is four 7years or until a successor is appointed, whichever is later.8(5) If a vacancy occurs on the board, the governor shall appoint an 9individual to fill the vacancy for the remaining term in the same manner as 10the original appointment.11(6) The governor may remove a member of the board for 12incompetence, malfeasance, misfeasance or nonfeasance in office, or any 13other good cause.14(c) (1) The governor shall call the first meeting of the board. At the 15first meeting, the board shall elect from among its members a chairperson 16and other officers as such board considers necessary or appropriate. After 17the first meeting, the board shall meet at least quarterly or more frequently 18at the call of the chairperson or if requested by a quorum of its members.19(2) A majority of the members of the board shall constitute a quorum 20for transacting business. Except as otherwise provided in this subsection, a 21majority of the members present and serving is required for official action 22of the board.23(d) Except as otherwise provided in this subsection, a writing that is 24prepared, owned, used, in the possession of or retained by the board in 25performing an official function is subject to the Kansas open records act. A 26writing containing a trade secret or proprietary information shall be 27confidential and privileged and not be subject to the provisions of the 28Kansas open records act as provided by K.S.A. 45-215 et seq., and 29amendments thereto. The provisions of this subsection shall expire on July 301, 2030, unless the legislature reviews and reenacts this provision pursuant 31to K.S.A. 45-229, and amendments thereto, prior to July 1, 2030.32(e) The salaries and other expenses incurred by members of the board 33shall be subject to appropriations.34(f) As used in this section, "health equity" means attaining the highest 35level of health for all individuals, in which an individual has a fair and just 36opportunity to attain such individual's optimal health regardless of race, 37ethnicity, disability, sexual orientation, gender identity, socioeconomic 38status, geography, preferred language or other factor that affects access to 39healthcare and health outcomes.40Sec. 4. (a) There is hereby established the prescription drug 41affordability stakeholder council within the department.42(1) Subject to paragraph 2, the council shall consist of the following 4321 members:1(A) Seven members appointed by the governor as follows:2(i) One individual representing manufacturers of brand name drugs;3(ii) one individual representing manufacturers of generic drugs;4(iii) one individual representing employers;5(iv) one individual representing pharmacy benefit managers;6(v) one individual representing pharmacists;7(vi) one individual representing a mutual insurance company. The 8mutual insurance company under this subparagraph shall not be an entity 9that, directly or indirectly through one or more intermediaries, controls, is 10controlled by or is under common control with the managed care 11organization; and12(vii) one member of the public;13(B) seven members appointed by the governor from a list of 14nominees submitted by the speaker of the house of representatives. The list 15of nominees shall include individuals who represent the following:16(i) A statewide organization that advocates for senior citizens;17(ii) a statewide organization that advocates for healthcare;18(iii) a statewide organization that advocates for diversity within 19communities;20(iv) a labor union;21(v) researchers who specialize in prescription drug products; and22(vi) the public; and23(C) seven members appointed by the governor from a list of 24nominees submitted by the senate majority leader. The list of nominees 25shall include individuals who represent each of the following:26(i) Physicians;27(ii) nurses;28(iii) hospitals;29(iv) managed care organizations. The managed care organization 30under this clause shall not be an entity that, directly or indirectly, through 31one or more intermediaries, controls, is controlled by or is under common 32control with the mutual insurance company under paragraph (1)(A)(vi);33(v) clinical researchers; and34(vi) the public.35(2) The governor shall ensure that the members appointed to the 36council have knowledge in one or more of the following areas:37(A) The pharmaceutical business model;38(B) supply chain business models;39(C) the practice of medicine or clinical training;40(D) consumer or patient perspectives;41(E) healthcare costs trends; and42(F) clinical and health services research.43(b) The governor shall appoint seven of the initial members of the 1council to one-year-terms, seven of the initial members to two-year terms 2and seven of the initial members to three year terms. After the initial 3appointments, the term of a member of the council is three years or until a 4successor is appointed, whichever is later.5(1) If a vacancy occurs on the council, the governor shall appoint an 6individual to fill the vacancy for the remaining term in the same manner as 7the original appointment.8(2) The governor may remove a member of the council for 9incompetence, malfeasance, misfeasance or nonfeasance in office or any 10other good cause.11(3) At the first meeting of the council, the council shall elect from 12among its members a chairperson and other officers as such council 13considers necessary or appropriate. After the first meeting, the council 14shall meet at least quarterly or more frequently at the call of the 15chairperson or if requested by a quorum of its members.16(4) A majority of the members of the council shall constitute a 17quorum for transacting business. A majority of the members present and 18serving is required for official action of the council.19(c) Except as otherwise provided in this subsection, a writing that is 20prepared, owned, used, in the possession of, or retained by the council in 21performing an official function is subject to the Kansas open records act. A 22writing containing a trade secret or proprietary information shall be 23confidential and privileged and not be subject to the provisions of the 24Kansas open records act as provided by K.S.A. 45-215 et seq., and 25amendments thereto. The provisions of this subsection shall expire on July 261, 2030, unless the legislature reviews and reenacts this provision pursuant 27to K.S.A. 45-229, and amendments thereto, prior to July 1, 2030.28(d) Members of the council attending meetings authorized by the 29council shall be paid amounts as provided in K.S.A. 75-3223(3), and 30amendments thereto.31(e) The council shall assist the board in making decisions required 32under this act.33Sec. 5. (a) Beginning on January 1, 2027, subject to subsection (b), 34the board, in35consultation with the council, shall select one or more prescription drug 36products based on any of the following criteria:37(1) The prescription drug product is a brand name drug or a biologic 38that, as adjusted annually for inflation in accordance with the consumer 39price index, has a wholesale acquisition cost of $60,000 or more per year 40or per course of treatment has a wholesale acquisition cost increase of 41$3,000 or more in any 12-month period;42(2) the prescription drug product is a biosimilar that has a wholesale 43acquisition cost that is not at least 15% lower than the referenced brand 1biologic; or2(3) the prescription drug product is a generic drug that, as adjusted 3annually for inflation in accordance with the consumer price index, has a 4wholesale acquisition cost that:5(A) Is $100 or more for any of the following:6(i) A 30-day supply that lasts a patient for a period of 30 consecutive 7days based on the recommended dosage approved for labeling by the 8United States food and drug administration;9(ii) a supply that lasts a patient for less than 30 days based on the 10recommended dosage approved for labeling by the United States food and 11drug administration; and12(iii) one unit of the drug if the labeling approved by the United States 13food and drug administration does not recommend a finite dosage; and14(B) increased by 200% or more during the immediately preceding 12-15month period, as determined by the difference between the resulting 16wholesale acquisition cost and the average wholesale acquisition cost 17reported over the immediately preceding 12 months; or18(4) the prescription drug product is a prescription drug product that 19may create affordability challenges for healthcare systems in this state and 20patients, including, but not limited to, a prescription drug product needed 21to address a public health emergency.22(b) In selecting one or more prescription drug products under 23subsection (a), the board shall not be required to identify each prescription 24drug product that meets the criteria described in subsection (a).25(1) The board shall determine whether to conduct a cost and 26affordability review for each prescription drug product that is selected 27under subsection (a). In making a determination under this subsection, the 28board shall consider input from the council and the average patient cost 29share for each prescription drug product.30(2) If the board conducts a cost and affordability review of a 31prescription drug product, the board may consider when conducting the 32review any document or research related to the manufacturer's selection of 33the introductory price or price increase of the prescription drug product, 34including life cycle management, net average price in this state, market 35competition, projected revenue and, subject to subsection (e), the 36estimated cost-effectiveness of the prescription drug product. In its review, 37the board shall determine whether the use of a prescription drug product 38that is fully consistent with the labeling approved by the United States 39food and drug administration or standard medical practice for the 40prescription drug product has led or will lead to affordability challenges to 41healthcare systems in this state or high out-of-pocket costs for patients in 42this state. In making its determination under this subsection, the board 43shall consider any information that a manufacturer chooses to provide to 1the board and all of the following factors, to the extent practicable:2(A) The wholesale acquisition cost for the prescription drug product 3sold in this state;4(B) the average monetary price concession, discount or rebate that the 5manufacturer provides or is expected to provide to health insurers and 6pharmacy benefit managers in this state, expressed as a percent of the 7wholesale acquisition cost for the prescription drug product under review;8(C) the price at which therapeutic alternatives for the prescription 9drug product have been sold in this state;10(D) the average monetary concession, discount or rebate that another 11manufacturer provides or is expected to provide to health insurers and 12pharmacy benefit managers in this state for therapeutic alternatives;13(E) the cost to health insurers based on patient access consistent with 14United States food and drug administration labeled indications or 15recognized standard medical practice;16(F) the impact on patient access resulting from the cost of the 17prescription drug product relative to insurance benefit design;18(G) the current or expected dollar value of drug-specific patient 19access programs that are supported by the manufacturer;20(H) the relative financial impact to health, medical or social service 21costs as can be quantified and compared to baseline effects of existing 22therapeutic alternatives;23(I) the average patient copay or other cost-sharing measures for the 24prescription drug product in this state; and25(J) any other factor established by the board.26(c) If the board determines that spending on a prescription drug 27product reviewed under this section has led or will lead to affordability 28challenges to healthcare systems in this state or high out-of-pocket costs 29for patients in this state, the board may, subject to subsection (d), adopt 30rules and regulations establishing an upper payment limit for the 31prescription drug product. In establishing an upper payment limit under 32this subsection, the board shall consider all of the following:33(1) Relevant administrative costs related to supplying or stocking the 34prescription drug product; and35(2) the impact of an upper payment limit for the prescription drug 36product on 340-B program entities.37(d) An upper payment limit established under this section shall not 38include professional dispensing fees.39(e) If the board considers the estimated cost-effectiveness of a 40prescription drug product under this section, the board:41(1) Shall not use a cost-per-quality adjusted life year, or a similar 42measure, to identify a subpopulation for which a prescription drug product 43would be less cost-effective due to severity of illness, age or preexisting 1disability; and2(2) if the board uses a cost-effectiveness analysis for a prescription drug 3product that extends an individual's life, the board shall use a cost-4effectiveness analysis that weighs the value of all additional lifetime 5gained equally for any individual, regardless of the severity of illness, age 6or preexisting disability.7(f) An upper payment limit established under this section shall take 8effect on the date adopted by the board by rule and regulation, except that 9such date shall not be sooner than six months after the date that the upper 10payment limit is established.11Sec. 6. (a) Except as otherwise provided in subsection (b), if the 12board establishes an upper payment limit under section 5, and amendments 13thereto, for a prescription drug product intended for use by individuals in 14this state, beginning on the effective date of the upper payment limit, a 15prescription drug product purchaser or third-party payer shall not 16purchase, bill or reimburse for the prescription drug product in an amount 17that exceeds the upper payment limit, regardless of whether the 18prescription drug product is dispensed or distributed in person, by mail or 19by other means.20(b) A prescription drug product purchaser or third-party payer shall 21not reimburse a pharmacy for a prescription drug product in an amount 22that is less than an upper payment limit established under section 5, and 23amendments thereto, for the prescription drug product.24(c) The attorney general may investigate a violation of this section 25and may commence a civil action against a person for appropriate relief, 26including, but not limited to, injunctive relief for a violation of this section.27(d) This section shall not prohibit any other sanction against a 28prescription drug product purchaser or third-party payor as provided by 29law.30(e) A person aggrieved by a decision of the board under this act may 31request an appeal within 30 days. A hearing and appeal is subject to the 32Kansas administrative procedure act.33(f) The board may adopt rules and regulations to implement and 34administer this act, and the board may enter into contracts with third 35parties to assist the board in carrying out its duties under this act.36Sec. 7. There is hereby established in the state treasury the 37prescription drug affordability fund, which shall be administered by the 38commissioner. All expenditures from the prescription drug affordability 39fund shall be to fund the board and for costs expended by the department 40to implement and administer the prescription drug cost and affordability 41review act. All expenditures from the prescription drug affordability fund 42shall be made in accordance with appropriation acts upon warrants of the 43director of accounts and reports issued pursuant to vouchers approved by 1the commissioner or the designee of the commissioner. All moneys 2received by the board for the prescription drug cost and affordability 3review act shall be deposited in the state treasury in accordance with the 4provisions of K.S.A. 75-4215, and amendments thereto. Upon receipt of 5each such remittance, the state treasurer shall deposit the entire amount in 6the state treasury to the credit of the prescription drug affordability fund.7Sec. 8. (a) Beginning in 2026, on or before December 31 of each 8year, the board shall submit a written report to the legislature that includes 9all of the following information: 10(1) Price trends for prescription drug products;11(2) the number of prescription drug products that were subject to 12board review, including the results of the review and the number and 13disposition of appeals of board decisions; and14(3) any recommendations that the board may have on further 15legislation to make prescription drug products more affordable in this 16state.17(b) Prior to the first date of the regular legislative session of 2027, the 18board shall conduct a one-time study on all of the following and report its 19findings to the legislature:20(1) The prices of generic drugs on a year-to-year basis;21(2) the degree to which the prices of generic drugs affect yearly 22insurance premium charges;23(3) annual changes in insurance cost-sharing for generic drugs;24(4) the potential for and history of drug shortages;25(5) the degree to which the prices of generic drugs affect yearly 26medical assistance program spending in this state;27(6) the impact of an upper payment limit on 340-B program entities; 28and29(7) any other issue that the board considers relevant.30Sec. 9. This act shall take effect and be in force from and after its 31publication in the statute book. search keyboard_arrow_up keyboard_arrow_down Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 arrow_upward Top Kansas State Legislature300 SW 10th Ave, Topeka, KS 66612
Ad Astra Per Aspera
Kansas Legislative HotlineIn-State: 1-800-432-3924
Out-of-State: 785-296-2149
Government
- Legislators
- House
- Representatives
- Senate
- Senators
- Committees
Resources
- Bills & Measures
- Today
- Live
- Journals
- Calendars
- Archived Records
- Laws
- Search
- RSS Feeds
Support
- Contact Us
- Accessibility
- Privacy Policy
- Visit Us
Official text from the Kansas Legislature. Formatting has been adapted for reading on Ratifi.